Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 448-453

  Fedorenko, Inna V ^a   Fang, Bin ^a   Koomen, John M ^a   Gibney, Geoffrey T ^a   Smalley, Keiran S M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Amuvatinib; BRAF; Melanoma; MP470; NRAS; Receptor tyrosine kinase

Indexed keywords

AMUVATINIB; B RAF KINASE; AXL RECEPTOR TYROSINE KINASE; BRAF PROTEIN, HUMAN; GROWTH ARREST-SPECIFIC PROTEIN 6; LIGAND; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE; STEM CELL FACTOR RECEPTOR;

ARTICLE; CANCER CELL LINE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MELANOMA; ONCOGENE N RAS; PRIORITY JOURNAL; APOPTOSIS; CELL CYCLE; COHORT ANALYSIS; CULTURE TECHNIQUE; GENETICS; IC50; METABOLISM; MUTATION; ONCOGENE RAS; PROTEOMICS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL LINE, TUMOR; COHORT STUDIES; DNA DAMAGE; GENES, RAS; HUMANS; INHIBITORY CONCENTRATION 50; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MELANOMA; MUTATION; PROTEOMICS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84910081356     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000103     Document Type: Article

References (20)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
2. Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2013;32:3009-3018.
3. Marquette A, Andre J, Bagot M, Bensussan A, Dumaz N. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol 2011;18:584-591.
4. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337-341.
5. Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, et al. Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene 2010;29:2449-2456.
6. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, Van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-256.
7. Molhoek KR, Shada AL, Smolkin M, Chowbina S, Papin J, Brautigan DL, Slingluff CL Jr. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res 2011;21:274-284.
8. Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res 2013;26:527-541.
9. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res 2012;18:2184-2198.
10. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-1144.
11. Tafreshi NK, Silva A, Estrella VC, McCardle TW, Chen T, Jeune-Smith Y, et al. In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharm 2013;10:3175-3185.
12. Sensi M, Catani M, Castellano G, Nicolini G, Alciato F, Tragni G, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol 2011;131:2448-2457.
13. Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 2009;9:142.
14. Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, et al. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 2013;6:92.
15. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA 2013;110:4015-4020.
16. Zhao H, Luoto KR, Meng AX, Bristow RG. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemotherapies in part by inhibiting homologous recombination. Radiother Oncol 2011;101:59-65.
17. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012;18:1503-1510.
18. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668-682.
19. Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, et al. Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib. Clin Cancer Res 2014 [Epub ahead of print].
20. Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, et al. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics 2014 [Epub ahead of print].